Updated:
Bukwang Pharmaceutical Co.
Bukwang Pharmaceutical Co. is a South Korean drugmaker with a CNS and oncology pipeline, open-innovation R&D model, and ESG framework.
Bukwang Pharmaceutical Co.
Bukwang Pharmaceutical Co. is a South Korean pharmaceutical company headquartered in Seoul. The firm's website outlines a commitment to R&D and open-innovation, with a stated goal of becoming a global pharmaceutical company. Bukwang's R&D pipeline centers on central nervous system and oncology therapies. Lead candidates include Lurasidone, a dopamine receptor antagonist for schizophrenia and bipolar depression; JM-010, a drug-repurposing candidate for Parkinson's disease levodopa-induced dyskinesia; and SOL-804, a metastatic castration-resistant prostate cancer therapy developed by subsidiary Dyna Therapeutics. The company pursues joint ventures, research collaborations, and M&A to expand its pipeline. Bukwang manufactures prescription drugs, OTC products, health-functional foods, and household goods. The company also has a subsidiary, Dyna Therapeutics, focused on formulation development. No total professionals, AUM, or recent operational events were disclosed on the firm's website. The firm maintains an ESG framework covering environmental policy, social responsibility, and governance. Bukwang's structural differentiator is its open-innovation model — explicitly combining external technologies with internal R&D capabilities to accelerate drug development and commercialization. The firm lists no named investment professionals, and no external sources confirm AUM or deployment figures.
General information
Firm type
other
Year founded
—
AUM
Undisclosed
Location
Region
Asia
Country
South Korea
City
Seoul
Corporate office
Seoul, South Korea
Sector focus
Frequently asked questions
What therapeutic areas does Bukwang Pharmaceutical Co. focus on?
Bukwang's R&D pipeline targets central nervous system disorders (schizophrenia, bipolar depression, Parkinson's disease) and oncology (metastatic castration-resistant prostate cancer). Their lead candidates include Lurasidone, JM-010, and SOL-804 (per the firm's website).
What is Bukwang's approach to drug development?
Bukwang pursues an open-innovation strategy, combining external technologies with internal R&D capabilities through joint ventures, research collaborations, and M&A. This approach aims to improve R&D efficiency and commercialization outcomes (per the firm's website).
Does Bukwang have any subsidiaries?
Yes, Bukwang lists Dyna Therapeutics as a subsidiary, a formulation development specialist developing SOL-804, a therapy for metastatic castration-resistant prostate cancer (per the firm's website).
What types of products does Bukwang manufacture?
Bukwang produces prescription drugs, over-the-counter medicines, health-functional foods, and household goods. The company's product lines are categorized on its website under '처방의약품', '일반의약품', '건강기능식품', and '생활용품'.
What is Bukwang's ESG focus?
Bukwang's ESG framework covers environmental policy, social responsibility (labor, human rights, social contribution), and governance (ethics, anti-corruption, compliance). The firm publishes an ESG board and a cyber whistleblower system on its website.
Profile maintained by Altss using OSINT (open-source intelligence), regulatory filings, licensed data partners, and verified direct submissions. Read the methodology. Last updated: . Continuous refresh with full update cycles at least every 30 days.
Need institutional-grade insight on family offices?
Altss delivers:
Prefer a guided tour?
We’ll walk you through: